13 completed, 2 active not recruiting, 1 unknown. 16 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 13, Active not recruiting 2, Unknown 1 |
| Phase 1 | 4 | Completed 3, Unknown 1 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
Follow ibudilast: new trials by email Literature Review of ibudilast trials Research Report on ibudilast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Ibudilast, Pentoxifylline, Placebo - Long COVID, Post COVID Condition | Phase 2 / Phase 3 | Completed | University Health Network, Toronto | 460 | 2023-05-31 | 2026-02-23 |
| Ibudilast for Treating Alcohol Use Disorder Ibudilast, Medical management, Placebo - Alcohol Use Disorder (AUD), Alcoholism | Phase 2 | Active not recruiting | University of Pennsylvania | 50 | 2023-01-14 | 2026-06-03 |
| Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS Ibudilast, Placebo - Pneumonia, Viral | Phase 2 | Completed | MediciNova | 34 | 2021-01-11 | 2024-10-30 |
| Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS MN-166, placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Active not recruiting | MediciNova | 234 | 2020-05-28 | 2026-03-06 |
| Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users Ibudilast, Placebo Oral Tablet - Methamphetamine-dependence | Phase 2 | Completed | VA Office of Research and Development | 176 | 2019-05-01 | 2026-02-02 |
| Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma MN-166, Temozolomide - Glioblastoma, Recurrent Glioblastoma | Phase 1 / Phase 2 | Completed | MediciNova | 64 | 2018-12-29 | 2025-05-21 |
| Ibudilast for the Treatment of Alcohol Use Disorder Ibudilast, Placebo oral capsule - Alcohol Use Disorder | Phase 2 | Completed | University of California, Los Angeles | 102 | 2018-10-01 | 2024-11-27 |
| Ibudilast and Withdrawal-Related Dysphoria Ibudilast, Placebo - Alcohol Use Disorder | Phase 2 | Completed | University of California, Los Angeles | 52 | 2018-07-16 | 2021-10-07 |
| A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS) ibudilast, Ibudilast - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Completed | MediciNova | 35 | 2016-05-06 | 2024-09-24 |
| Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) Placebo (for MN-166), MN-166, riluzole - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | MediciNova | 70 | 2014-09-01 | 2021-11-05 |
| Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis ibudilast, Placebo oral capsule - Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | Phase 2 | Completed | MediciNova | 255 | 2013-11-01 | 2020-07-28 |
| Trial of Ibudilast for Methamphetamine Dependence Ibudilast, Placebo - Methamphetamine Dependence, HIV Infection | Phase 2 | Completed | University of California, Los Angeles | 125 | 2013-07-01 | 2019-01-30 |
| Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers MN-166 (50 mg) First, Placebo First - Opioid Abuse, Opioid Dependence | Phase 2 | Completed | New York State Psychiatric Institute | 28 | 2012-11-01 | 2017-08-17 |
| Ibudilast in the Treatment of Medication Overuse Headache Ibudilast, Placebo - Medication Overuse Headache | Phase 1 / Phase 2 | Unknown | University of Adelaide | 40 | 2011-04-01 | 2013-02-06 |
| Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal AV411, Placebo (PCB) - Opioid-Related Disorders | Phase 2 | Completed | New York State Psychiatric Institute | 30 | 2008-10-01 | 2016-12-05 |
| Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain AV411 - Diabetic Neuropathy | Phase 1 / Phase 2 | Completed | Avigen | 36 | 2006-09-01 | 2007-12-19 |
Alcoholism (3) · Amyotrophic Lateral Sclerosis (3) · Opioid-Related Disorders (2) · Agnosia (1) · COVID-19 (1) · Diabetic Neuropathies (1) · Glioblastoma (1) · HIV Infections (1) · Headache Disorders, Secondary (1) · Multiple Sclerosis, Chronic Progressive (1) · Neuroinflammatory Diseases (1) · Pain (1) · Pneumonia (1) · Pneumonia, Viral (1) · Post-Acute COVID-19 Syndrome (1)
MediciNova (6) · University of California, Los Angeles (3) · New York State Psychiatric Institute (2) · Avigen (1) · University Health Network, Toronto (1) · University of Adelaide (1) · University of Pennsylvania (1) · VA Office of Research and Development (1)
United States (13) · Australia (2) · Canada (2)
Kazuko Matsuda, MD PhD MPH (2) · Sandra D Comer, PhD (2) · Angela M Cheung, MD,PhD (1) · Benjamin R Brooks, M.D. (1) · George Tomlinson, PhD (1) · Henry R Kranzler, MD (1) · Keith Heinzerling, MD (1) · Lara A Ray, PhD (1) · Lara A. Ray, PhD (1) · Milky Kohno, PhD (1) · Paul Rolan, MD FRACP (1) · Peter Juni, MD, PhD (1) · Robert J Fox, MD, FAAN (1) · Suma Babu, MBBS, MPH (1)
PMID 25175864, PMID 25975386, PMID 30157388, PMID 32912290, PMID 33054533, PMID 34016561, PMID 34585396, PMID 34816762, PMID 36008843, PMID 37537928, PMID 39217272, PMID 40305022, PMID 41342004, PMID 41509523, PMID 41603979, PMID 41928198
P50DA009236 (2), R01AA026190 (1), R01DA035054 (1), U01NS082329 (1)